Compare NHS & BIOA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NHS | BIOA |
|---|---|---|
| Founded | 2003 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 251.6M | 255.6M |
| IPO Year | N/A | 2024 |
| Metric | NHS | BIOA |
|---|---|---|
| Price | $5.58 | $5.31 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $32.56 |
| AVG Volume (30 Days) | 294.7K | ★ 774.7K |
| Earning Date | 01-01-0001 | 11-05-2026 |
| Dividend Yield | ★ 13.44% | N/A |
| EPS Growth | N/A | ★ 66.21 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $8,995,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $97.72 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.26 | $4.81 |
| 52 Week High | $7.75 | $25.96 |
| Indicator | NHS | BIOA |
|---|---|---|
| Relative Strength Index (RSI) | 58.84 | 36.87 |
| Support Level | $5.26 | $4.81 |
| Resistance Level | $6.12 | $8.53 |
| Average True Range (ATR) | 0.06 | 0.44 |
| MACD | 0.03 | 0.15 |
| Stochastic Oscillator | 91.07 | 34.06 |
Neuberger Berman High Yield Strategies Fund Inc is a diversified, closed-end management investment company. The company invests in high yield debt securities market. The Fund uses leverage to pursue its investment objective. The Fund may invest in a variety of direct debt instruments, including bank loans, notes and other interests in amounts owed to financial institutions by borrowers, such as companies and governments. Corporate loans in which the Fund may invest will consist of direct obligations of borrowers. The Fund may invest in corporate loans at origination as a co-lender or may acquire loans in the secondary market by purchasing participations in, assignments of or novations of corporate loans.
Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging. The company's technology platform and differentiated human datasets enable the identification of targets based on insights into molecular changes that drive aging. The Company operates and manages its business as one reportable and operating segment, which is the business of extending healthy human life by targeting molecular causes of aging.